Company ProfileAt AVI BioPharma we are focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as select other diseases targets. By leveraging our highly differentiated RNA antisense-based technology platform, we have built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses.
By applying pioneering technologies developed and optimized by AVI, we are able to target a broad range of... More >> | | Stock Information |
|
Recent News| 08/24/10 | AVI BioPharma Announces Positive Results Against Human Pandemic H1N1
Influenza Virus in Preclinical Studies of AVI-7100| AVI-7100 Demonstrates Statistically Significant Activity Versus Saline and Tamiflu(R) Controls, Up to 3.9 Log Greater Reduction in Average Viral Titer AVI BioPharma and US Department of Defense Conduct Successful Rapid Response Exercise Against Real-World Threat, Pandemic H1N1 Virus
BOTHELL, WA, Aug 24, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today announced positive results from two preclinical studies
evaluating the therapeutic p... |
|  | | 08/23/10 | Nature Medicine Publishes AVI BioPharma Preclinical Studies
Demonstrating Post-Exposure Efficacy of PMOplus(TM) Oligomers Against
Ebola and Marburg Viruses| BOTHELL, WA, Aug 23, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, today announced the publication online in Nature
Medicine of new preclinical data demonstrating that AVI-6002 and
AVI-6003, the respective lead therapeutic candidates against Ebola
and Marburg viruses, both employing AVI's advanced PMOplus(TM)
chemistry, provide post exposure efficacy in non-human primates.
Treatment of Ebola virus-infected primates with AVI-6002 l... |
| | | 08/09/10 | AVI BioPharma Announces Second Quarter 2010 Financial Results| Financial Results and Corporate Update Conference Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific)
BOTHELL, WA, Aug 09, 2010 (MARKETWIRE via COMTEX) --
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today reported financial results for the three and six months ended June 30, 2010.
For the second quarter of 2010 AVI reported an operating loss of $7.7 million compared with an operating loss of $5.1 million in the second quarter of 2009. The increase in the opera... |
| | | 08/02/10 | AVI BioPharma Announces Second Quarter 2010 Financial Results and
Corporate Update Conference Call| BOTHELL, WA, Aug 02, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, will report second quarter 2010 financial results after
the NASDAQ Global Market closes on Monday, August 9, 2010.
Subsequently, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time), J.
David Boyle II, AVI's Interim President and Chief Executive Officer,
and Chief Financial Officer, will host a conference call to discuss
second quarter 2010 financial results and to p... |
| |
|
More Releases
Upcoming Events09/12/10
through
09/15/10 | | Rodman & Renshaw Global Investment Conference | | Location | New York, NY |
| 09/20/10
through
09/23/10 | | UBS Global Life Sciences Conference | | Location | New York, NY |
| 09/27/10
through
09/29/10 | | JMP Securities LLC Healthcare Focus Conference | | Location | New York, NY |
|
|
More Events |
